FinancialNewsMedia.com

FinancialNewsMedia.com
Professional News Dissemination Services

Tuesday, June 23, 2015

Cabo Verde Capital Inc. Reaches Agreement on Management Contract for New Hotel Asset in Cabo Verde

WILMINGTON, Del. - (http://www.financialnewsmedia.com News Alert) - Cabo Verde Capital Inc. (OTC:CAPV) (the "Company") is pleased to announce that it has reached an agreement in principle with a global hotel  management company for the Company's hotel project In Santo Antao.  The Company is developing the project in the Republic of Cabo Verde on the island of Santo Antao.    The site is over 60,000 sq.m.  Definitive documentation is expected to be signed in the next few days and will include details of the commercial terms, that reflect Cabo Verde Capital's business practices which are built on a platform of de-risk and exit strategy in their projects through lease agreements.

About Cabo Verde Capital Inc.

Cabo Verde Capital's activities are based on three main pillars: Real Estate, Hospitality and Casino development and the exploitation of these three segments.

This news release was prepared on behalf of the Board of Directors, which accepts full responsibility for its contents. For more information please contact Corporate Relations at info@caboverdecapital.com.

John Duggan, President

Forward-looking Statement:

THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS," AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE.EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH REAL ESTATE DEVELOPMENT AND FUNDING AS WELL AS THE RISKS SHOWN IN THE COMPANY'S MOST RECENT ANNUAL AND QUARTERLY REPORTS FILED AND PUBLISHED ON WWW.OTCMARKETS.COM, RESPECTIVELY, AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY''S ABILITY AND LEVEL OF SUPPORT FOR ITS DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY''S EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE.

INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED AND PUBLISHED FROM TIME-TO-TIME ON WWW.OTCMARKETS.COM. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKES FULL RESPONSIBILITY FOR ITS CONTENTS. NO SECURITIES REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALLTHERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

Contact Info:

www.caboverdecapital.com  |  info@caboverdecapital.com   |  Corporate Relations: +1 (302) 824-7077

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cabo-verde-capital-inc-reaches-agreement-on-management-contract-for-new-hotel-asset-in-cabo-verde-300103193.html

SOURCE Cabo Verde Capital Inc.


FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated two thousand five hundred dollars for Cabo Verde Capital Inc. news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF Cabo Verde Capital Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Tuesday, June 16, 2015

North American Cannabis Holdings Introduces The 'AmeriCanna Cafe,' a Cannabis Infused Beverage Shop Chain

A Pending Nutritional Beverage Cafe Acquisition Is Intended To Accelerate The AmeriCanna Cafe Destination Beverage Franchise Rollout

DALLAS,  - (http://www.financialnewsmedia.com News Alert) - North American Cannabis Holdings, Inc. (OTC: USMJ) introduces The AmeriCanna Cafe, a new subsidiary founded on the results of an earlier pilot program.

The AmeriCanna Cafe is a destination beverage company designed to let consumers interface with trained staff to learn about the specific benefits of cannabis and to select healthy and refreshing cannabis infused beverages.  The menu will include custom blended hemp infused coffee, cold pressed juices and smoothies in addition to carrying raw hemp seeds and other hemp infused foods.  As state and federal law permits, THC infused beverages and foods will be added to the menu.

"Ex-Microsoft executive, Jamen Shively, will have some competition in becoming the 'Starbucks of [Cannabis],' said North American Cannabis Holdings CEO, Steven Rash.  "We've learned a few things in our beverage pilot that we believe give us an edge in the cannabis destination beverage market, not to mention a pending acquisition that once finalized, we believe will give us yet another leg up."

The AmeriCanna Cafe subsidiary is expected to expand rapidly through a national franchise model accelerated by North American Cannabis Holdings'

1.    Existing DuBe Hemp Energy drink distribution business,
2.    Existing Hippie Butter joint venture, and
3.    The previously announced pending acquisition of an existing, ten year old fitness cafe operation already serving nutritional food and beverages.

The AmeriCanna Cafe originates from one of a series of pilots starting back in 2013 under North American Cannabis Holdings' American Seed & Oil Company subsidiary established to conduct various pilots in the legal cannabis sector in order to explore a variety of high growth potential business opportunities.

The founders of the target acquisition come from a collection of nutritional experts, fitness consultants, and other fitness industry professionals that developed a nutritionally superior, sophisticated line of niche beverages.  North American Cannabis Holdings has been working with the target acquisition over the last year to develop the cannabis destination beverage cafe concept.  Completion of the acquisition is imminently anticipated.

About North American Cannabis Holdings, Inc.

North American Cannabis Holdings, Inc. (OTC: USMJ) is founded on the core belief that cannabis makes people's lives better.  Cannabis can fight disease, improve wellness and do so in an environmentally sustainable manner.  North American Cannabis Holdings is dedicated to finding the best possible applications for cannabis to serve consumers.  For more information please visit www.growusmj.com.

Follow the company on Twitter: http://twitter.com/US_HEMP

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.


CONTACT:
Mike Murphree
Phone: +1-972-528-0162
Email:mike.murphree@americanseedandoil.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/north-american-cannabis-holdings-introduces-the-americanna-cafe-a-cannabis-infused-beverage-shop-chain-300099659.html

SOURCE North American Cannabis Holdings, Inc.


FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated two thousand seven hundred dollars for North American Cannabis Holdings, Inc. news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF North American Cannabis Holdings, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Wednesday, June 10, 2015

PositiveID and DirectView Security Systems Enter Into Co-Marketing Agreement to Jointly Market Products to Homeland Security and First Responders

Companies to cross market PositiveID's biological detection and diagnostic solutions with DirectView's video surveillance and body worn camera technologies

DELRAY BEACH, Florida, - (http://www.financialnewsmedia.com News Alert) - PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a developer of biological detection and diagnostics solutions, announced today that it has entered a co-marketing agreement with DirectView Security Systems, Inc. ("DirectView") (OTC: DIRV), a provider of video surveillance systems including body worn cameras, to jointly market  the companies' products to homeland security and first responders.

PositiveID develops molecular diagnostic systems, including Firefly Dx, which is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly's applications for first responders include point-of-need, lab-quality detection of pathogenic organisms and detection of biological agents associated with weapons of mass destruction.

DirectView provides, among other products and services, body worn cameras, video storage servers, digital video recorders, and network video recorders, to address the needs of first responders.

"We are excited to enter into this co-marketing agreement with DirectView to include video surveillance solutions and body worn cameras to our line of first responder products," stated William J. Caragol, Chairman and CEO of PositiveID. "Through collaborating with companies like DirectView we accomplish two important goals: adding synergistic products and leveraging the sales channels of both companies to maximize our efforts and achieve better results."

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

About DirectView Holdings, Inc.

DirectView Holdings, Inc., together with its subsidiaries, provides video surveillance solutions and teleconferencing products and services to businesses and organizations. The company operates in two divisions, Security (Video Surveillance) and Video Conferencing. The Security division offers technologies in surveillance systems providing onsite and remote video and audio surveillance, digital video recording, and services. It also sells and installs surveillance systems; and sells maintenance agreements. The company sells its products and services in the United States and internationally through direct sales force, referrals, and its Websites. The Video Conferencing division offers teleconferencing products and services that enable clients to conduct remote meetings by linking participants in geographically dispersed locations. It is involved in the sale of conferencing services based upon usage, the sale and installation of video equipment, and the sale of maintenance agreements. This division primarily provides conferencing products and services to numerous organizations ranging from law firms, banks, high tech companies and government organizations. For more information visit our website at www.DirectView.com and connect with us on Twitter, LinkedIn, Facebook, and Google+.

Statements about PositiveID's future expectations, including the likelihood that Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results; the likelihood that through collaborating with companies like DirectView the Company accomplishes two important goals: adding synergistic products and leveraging the sales channels of both companies to maximize our efforts and achieve better results; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the bio-threat detection and rapid medical testing sectors; the Company's ability to complete the development of its Firefly Dx system; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 30, 2015, and 10-Qs filed on May 15, 2015, November 17, 2014, and August 14, 2014, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:
PositiveID Corporation
Allison Tomek
+1-561-805-8044
atomek@positiveidcorp.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/positiveid-and-directview-security-systems-enter-into-co-marketing-agreement-to-jointly-market-products-to-homeland-security-and-first-responders-300096970.html

SOURCE PositiveID Corporation


FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated two thousand dollars for PositiveID Corporation news coverage by the company.  FNMG HOLDS NO SHARES OF PositiveID Corporation

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer

SAN DIEGO, Calif., - (http://www.financialnewsmedia.com News Alert) - Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals  of the collaboration is to  address  questions  posed by the FDA regarding  Regn BioPharma, Inc.'s planned  Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability  of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.

"Using the immune system to treat cancer offers great potential in that the immune system destroys tumor cells, but then establishes immunological memory, which constantly patrols the body for rogue cells." Said Dr. Kesari, "Having served as a member of Regen's Scientific Advisory Board,  I am excited to be involved in this collaboration, in which we aim to help expediently address the questions posed by the FDA and allow for clinical entry of dCellVax." 

"As a company we have been fortunate to attract collaborators with established track records of bringing drugs from bench to bedside." Said Thomas Ichim, Ph.D, Chief Scientific Officer of Regen BioPharma.  "In addition to being an internationally renowned clinician, having participated in over 50 clinical trials, Dr. Kesari has been the author of over 200 scientific publications and is the inventor on numerous patents and patent applications in the area of oncology and immunology.  This combination of academic and clinical success is ideal for the current collaboration in which we are trying to address issues at the intersection between basic science and applied medicine. This  collaboration will  provide us the benefit of  Dr. Kesari's  years of expertise in oncology drug development and clinical practice."

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia. Regen is majority controlled by Bio-Matrix Scientific Group Inc. (OTC PINK: BMSN).

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404
www.regenbiopharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cancer-clinical-trials-expert-dr-santosh-kesari-to-assist-regen-biopharma-inc-in-addressing-fda-questions-regarding-planned-dcellvax-immunotherapy-clinical-trial-for-breast-cancer-300096983.html

SOURCE Regen BioPharma, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated three thousand dollars for Regen Biopharma, Inc.  news coverage by the company.  FNMG HOLDS NO SHARES OF Regen Biopharma, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Wednesday, June 3, 2015

Sunwin Stevia International Operates a New Manufacturing Facility of 500 Metric Tons of High-Grade Stevia Increasing its Total Manufacturing Capacity of High-Grade Stevia to 1,600 Metric Tons per Year

QUFU, China, - (http://www.financialnewsmedia.com News Alert) - Sunwin Stevia International, Inc. (OTCQB: SUWN, "Sunwin Stevia"), one of the top global suppliers of high quality stevia extracts including Rebaudioside A 98 and Rebaudioside A99, announced today that it has completed construction of a new manufacturing facility that can produce 500 metric tons of high-grade stevia per year.  The new facility has been in operation to produce high-grade stevia products on a commercial basis for the market.

In 2014 Sunwin Stevia invested approximately $2 million to start building this new facility in order to meet substantially increased demand for its high-grade stevia products. The new manufacturing facility is fully equipped with stainless steel equipment without any plastic while it has a fully automated system in order to prevent any potential contamination from operators and plastic. In addition, the new manufacturing facility uses the most advanced production equipment that is the first time to be used for stevia production in the industry, such as scraper with centrifuge and fluidized drying system.

As of now, Sunwin Stevia has approximately 1,600 metric tons in manufacturing capacity per year to produce high-grade stevia extract.  With these manufacturing facilities, Sunwin Stevia is able to deliver stevia products containing Rebaudioside A in a range of 50% to 99% with a format of powder, granular, or tablet.

Ms. Dongdong Lin, CEO of Sunwin Stevia stated, "We believe Sunwin Stevia becomes the largest manufacturer of high-grade stevia in the world.  We expect the total demand for stevia extract will reach a new level in 2016 and beyond.  Our state of the art manufacturing facilities lay a solid foundation to grow our stevia business. Our total manufacturing capacity will allow us to grow our annual revenues over $60 million.  We will actively market our stevia products in Europe, Asia, South America, and North America to become a dominant global high-grade stevia supplier for years to come."

About Sunwin Stevia International, Inc.

Sunwin Stevia International, Inc. (OTCQB: SUWN) engages in production and distribution of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in high quality stevia production, Sunwin Stevia has built an integrated firm with the farming and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin Stevia, please visit http://www.sunwininternational.com

Safe Harbor Statement

Sunwin Stevia International, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our ability to return our revenues to historical levels, our dependence on continued market acceptance of our products, competition, our ability to control our raw material costs, risks associated with operating in China, and other risk factors impacting our company, some of which may be beyond our control.  We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2014.

Contact:
Peisha Shen
U.S. Representative
Telephone: +1 (954) 363-7333
Facsimile: +1 (954) 363-7320
Email: ir@sunwininternational.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sunwin-stevia-international-operates-a-new-manufacturing-facility-of-500-metric-tons-of-highgrade-stevia-increasing-its-total-manufacturing-capacity-of-high-grade-stevia-to-1600-metric-tons-per-year-300093330.html

SOURCE Sunwin Stevia International, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated two thousand seven hundred dollars for Sunwin Stevia International, Inc news coverage by the company.  FNMG HOLDS NO SHARES OF Sunwin Stevia International, Inc

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.